PANews reported on October 21st that NewLimit, a longevity research company co-founded by Coinbase's CEO, retweeted a message from co-founder Jacob Kimmel stating that NewLimit has secured $45 million in additional funding from investors including Lilly Ventures, Duke University, S32, and Abstract, with participation from new and existing shareholders such as Kleiner Perkins, Dimension, Human Capital, and Boost VC. This round of financing stems from a technological breakthrough in their project to restore youthful liver function, with plans to initiate clinical studies in the coming years.